MedTrace Logo

Etanercept (Enbrel) in Ankylosing Spondylitis

NCT01289743 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2011-02-04

No results posted yet for this study

Summary

The study has the aim to investigate the efficacy and safety of etanercept in patients with active ankylosing spondylitis (AS) over 520 weeks.

Conditions

Interventions

DRUG

Etanercept

Etanercept 25 mg subcutaneously twice a week

Sponsors & Collaborators

  • Rheumazentrum Ruhrgebiet

    collaborator OTHER

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Joachim Sieper, Prof. Dr. · Charite University, Berlin, Germany

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28
Primary Completion
2003-09-30
Completion
2012-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01289743 on ClinicalTrials.gov